Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 22:53:46-54.
doi: 10.1016/j.euros.2023.03.013. eCollection 2023 Jul.

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

Juan Morote  1   2 , Ángel Borque-Fernando  3 , Marina Triquell  1   2 , Miriam Campistol  1   2 , Pol Servian  4 , José M Abascal  5   6 , Jacques Planas  1   2 , Olga Méndez  7 , Luis M Esteban  8 , Enrique Trilla  1   2
Affiliations

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

Juan Morote et al. Eur Urol Open Sci. .

Abstract

Background: Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS).

Objective: To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories.

Design setting and participants: A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions.

Outcome measurements and statistical analysis: Saved biopsies and undetected csPCa (grade group ≥2) were determined.

Results and limitations: The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5.

Conclusions: ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5.

Patient summary: Barcelona risk calculator was more helpful than Rotterdam risk calculator to select candidates for prostate biopsy.

Keywords: Clinically significant; Early detection; Magnetic resonance imaging; Predictive model; Prostate cancer; Risk calculator.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Violin plots of csPCa likelihoods of men without and with csPCa estimated with ROT MRI-RC and BCN MRI-RC. BCN = Barcelona; csPCa = clinically significant prostate cancer; MRI-RC = magnetic resonance imaging–based risk calculator; ROT = Rotterdam.
Fig. 2
Fig. 2
Calibration curves of (A) ROT MRI-RC and (B) BCN MRI-RC. BCN = Barcelona; MRI-RC = magnetic resonance imaging–based risk calculator; ROT = Rotterdam.
Fig. 3
Fig. 3
(A) Discrimination ability of csPCa of BCN MRI-RC and ROT MRI-RC presented with ROC curves, (B) net benefit of BCN MRI-RC and ROT MRI-RC over biopsying all men presented by DCAs, and (C) clinical utility of BCN MRI-RC and ROT MRI-RC showing the percentage of avoided biopsies and missed csPCa according to the threshold probability of csPCa by CUCs. BCN = Barcelona; csPCa = clinically significant prostate cancer; CUC = clinical utility curve; DCA = decision curve analysis; MRI-RC = magnetic resonance imaging–based risk calculator; ROT = Rotterdam.
Fig. 4
Fig. 4
Violin plots of csPCa likelihoods, estimated from (A) ROT MRI-RC and (B) BCN MRI-RC, in men without and with csPCa according to the PI-RADS categories. BCN = Barcelona; csPCa = clinically significant prostate cancer; MRI-RC = magnetic resonance imaging–based risk calculator; PI-RADS = Prostate Imaging Reporting and Data System; ROT = Rotterdam.
Fig. 5
Fig. 5
Discrimination ability presented by ROC curves, net benefit presented by DCAs, and clinical utility presented by CUCs, of BCN MRI-RC and ROT MRI-RC according to the PI-RADS categories: (A–C) PI-RADS <3, (D–F) PI-RADS 3, (G–I) PI-RADS 4, and (J–L) PI-RADS 5. BCN = Barcelona; csPCa = clinically significant prostate cancer; CUC = clinical utility curve; MRI-RC = magnetic resonance imaging–based risk calculator; PI-RADS = Prostate Imaging Reporting and Data System; ROT = Rotterdam.
See this image and copyright information in PMC

References

    1. Mottet N., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–262. - PubMed
    1. Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol. 2021;80:703–711. - PubMed
    1. Van Poppel H., Hogenhout R., Albers P., van den Bergh R.C.N., Barentsz J.O., Roobol M.J. European model for an organised risk-stratified early detection programme for prostate cancer. Eur Urol Oncol. 2021;10:731–739. - PubMed
    1. Schoots I.G., Padhani A.R., Rouvière O., Barentsz J.O., Richenberg J. Analysis of magnetic resonance imaging-directed biopsy strategies for changing the paradigm of prostate cancer diagnosis. Eur Urol Oncol. 2020;3:32–41. - PubMed
    1. Sathianathen N.J., Omer A., Harriss E., et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur Urol. 2020;78:402–414. - PubMed